Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 1/2017

01-03-2017

Osteoporosis in patients with diabetes after kidney transplantation

Authors: Elvira O. Gosmanova, Aidar R. Gosmanov

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2017

Login to get access

Abstract

Preexisting diabetes increases risk of fractures after kidney transplantation (KT). However, little is known about mechanisms and prevention of increased fragility in these patients. Pathophysiology of osteoporosis after KT is complex and characterized by high prevalence of adynamic bone disease. Despite high prevalence of preexisting diabetes in KT recipients, diabetes patients were underrepresented in the studies that explored mechanisms and treatments of osteoporosis after KT. Therefore, caution should be exercised before considering conventional fracture prevention strategies in this unique group of patients. Many traditional osteoporosis medications reduce bone turnover and, hence, can be ineffective or even harmful in diabetic patients after KT. Contrary to predictions, evidence from the studies conducted in mostly non-diabetic subjects demonstrated that bisphosphonates failed to reduce fracture rates after KT. Therefore, bisphosphonates use should be limited in diabetic patients until more evidence supporting their post-transplant efficacy is available. We recommend the following strategies that may help reduce fracture risk in diabetes subjects after KT such as adequate management of calcium, parathyroid hormone, and vitamin D levels, optimization of glycemic control, use of steroid-sparing immunosuppressive regimens, and fall prevention.
Literature
1.
go back to reference Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US renal data system 2015 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67(3 Suppl 1):S1–434. doi:10.1053/j.ajkd.2015.12.014. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US renal data system 2015 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67(3 Suppl 1):S1–434. doi:10.​1053/​j.​ajkd.​2015.​12.​014.
2.
go back to reference OPTN/SRTR Annual Report. 2004 annual report of the US organ procurement and transplantation network and the scientific registry of transplant recipients: Transplant data 1994-2003 Department of Health and Human Services, Health Resources and Services Administration, healthcare systems bureau, division of transplantation, Rockville, MD; united network for organ sharing, Richmond, VA; university renal research and education association, Ann Arbor. MI. 1999-2008;2009 OPTN/SRTR Annual Report. 2004 annual report of the US organ procurement and transplantation network and the scientific registry of transplant recipients: Transplant data 1994-2003 Department of Health and Human Services, Health Resources and Services Administration, healthcare systems bureau, division of transplantation, Rockville, MD; united network for organ sharing, Richmond, VA; university renal research and education association, Ann Arbor. MI. 1999-2008;2009
3.
go back to reference Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11(7):450–7.CrossRefPubMed Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11(7):450–7.CrossRefPubMed
5.
go back to reference Epstein S, Defeudis G, Manfrini S, Napoli N, Pozzilli P. Scientific Committee of the First International Symposium on D et al. diabetes and disordered bone metabolism (diabetic osteodystrophy): Time for recognition. Osteoporos Int. 2016;27(6):1931–51. doi:10.1007/s00198-015-3454-x.CrossRefPubMed Epstein S, Defeudis G, Manfrini S, Napoli N, Pozzilli P. Scientific Committee of the First International Symposium on D et al. diabetes and disordered bone metabolism (diabetic osteodystrophy): Time for recognition. Osteoporos Int. 2016;27(6):1931–51. doi:10.​1007/​s00198-015-3454-x.CrossRefPubMed
8.
go back to reference Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care. 2008;31(5):845–51. doi:10.2337/dc07-2270.CrossRefPubMed Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care. 2008;31(5):845–51. doi:10.​2337/​dc07-2270.CrossRefPubMed
9.
go back to reference Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, et al. Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(11):2142–50. doi:10.2337/dc15-1068.CrossRefPubMed Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, et al. Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(11):2142–50. doi:10.​2337/​dc15-1068.CrossRefPubMed
14.
go back to reference Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44(7):775–82.CrossRefPubMed Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44(7):775–82.CrossRefPubMed
17.
go back to reference Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323(1):22–7.CrossRefPubMed Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323(1):22–7.CrossRefPubMed
24.
go back to reference Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–8. doi:10.1038/sj.ki.5002009.CrossRefPubMed Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–8. doi:10.​1038/​sj.​ki.​5002009.CrossRefPubMed
25.
go back to reference Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53. doi:10.1038/sj.ki.5000414.CrossRefPubMed Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53. doi:10.​1038/​sj.​ki.​5000414.CrossRefPubMed
28.
go back to reference Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18(6):1159–66.CrossRefPubMed Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18(6):1159–66.CrossRefPubMed
31.
go back to reference Kidney Disease. Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. 2009;113:S1–130. doi:10.1038/ki.2009.188. Kidney Disease. Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. 2009;113:S1–130. doi:10.​1038/​ki.​2009.​188.
33.
go back to reference Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant. 1996;11(12):2430–8.CrossRefPubMed Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant. 1996;11(12):2430–8.CrossRefPubMed
34.
go back to reference Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int. 1995;47(5):1434–42.CrossRefPubMed Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int. 1995;47(5):1434–42.CrossRefPubMed
35.
37.
go back to reference Cavalier E, Bergmann P, Bruyere O, Delanaye P, Durnez A, Devogelaer JP, et al. The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: A consensus paper of the Belgian bone Club. Osteoporos Int. 2016;27(7):2181–95. doi:10.1007/s00198-016-3561-3.CrossRefPubMed Cavalier E, Bergmann P, Bruyere O, Delanaye P, Durnez A, Devogelaer JP, et al. The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: A consensus paper of the Belgian bone Club. Osteoporos Int. 2016;27(7):2181–95. doi:10.​1007/​s00198-016-3561-3.CrossRefPubMed
40.
go back to reference Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006;70(7):1358–66. doi:10.1038/sj.ki.5001754.CrossRefPubMed Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006;70(7):1358–66. doi:10.​1038/​sj.​ki.​5001754.CrossRefPubMed
42.
go back to reference Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial. J Am Soc Nephrol. 2015;26(6):1466–75. doi:10.1681/ASN.2014040414.CrossRefPubMed Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial. J Am Soc Nephrol. 2015;26(6):1466–75. doi:10.​1681/​ASN.​2014040414.CrossRefPubMed
46.
48.
go back to reference Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: A systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45(4):638–49.CrossRefPubMed Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: A systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45(4):638–49.CrossRefPubMed
52.
go back to reference Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation. 1999;67(9):1218–22.CrossRefPubMed Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation. 1999;67(9):1218–22.CrossRefPubMed
54.
55.
go back to reference Smets YF, van der Pijl JW, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA. Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. 1998;13(5):1250–5.CrossRefPubMed Smets YF, van der Pijl JW, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA. Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. 1998;13(5):1250–5.CrossRefPubMed
57.
go back to reference Kamenicky P, Mazziotti G, Lombes M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: Pathophysiological and clinical implications. Endocr Rev. 2014;35(2):234–81. doi:10.1210/er.2013-1071.CrossRefPubMed Kamenicky P, Mazziotti G, Lombes M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: Pathophysiological and clinical implications. Endocr Rev. 2014;35(2):234–81. doi:10.​1210/​er.​2013-1071.CrossRefPubMed
58.
go back to reference Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol. 2000;11(6):1093–9.PubMed Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol. 2000;11(6):1093–9.PubMed
59.
60.
go back to reference Gosmanova EO, Tangpricha V, Gosmanov AR. Endocrine-metabolic pathophysiologic conditions and treatment approaches after kidney transplantation. Endocrine practice: Official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2012;18(4):579–90. doi:10.4158/12016.RA.CrossRef Gosmanova EO, Tangpricha V, Gosmanov AR. Endocrine-metabolic pathophysiologic conditions and treatment approaches after kidney transplantation. Endocrine practice: Official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2012;18(4):579–90. doi:10.​4158/​12016.​RA.CrossRef
62.
go back to reference Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, et al. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant. 1998;13(Suppl 3):94–7.CrossRefPubMed Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, et al. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant. 1998;13(Suppl 3):94–7.CrossRefPubMed
63.
go back to reference Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653–63. doi:10.1111/ajt.12425.CrossRefPubMed Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653–63. doi:10.​1111/​ajt.​12425.CrossRefPubMed
64.
go back to reference Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography. Bone. 2006;39(2):345–52. doi:10.1016/j.bone.2006.01.161.CrossRefPubMed Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computed tomography. Bone. 2006;39(2):345–52. doi:10.​1016/​j.​bone.​2006.​01.​161.CrossRefPubMed
65.
go back to reference Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008;23(12):1974–82. doi:10.1359/jbmr.080805.CrossRefPubMedPubMedCentral Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008;23(12):1974–82. doi:10.​1359/​jbmr.​080805.CrossRefPubMedPubMedCentral
66.
67.
go back to reference Kan SL, Ning GZ, Chen LX, Zhou Y, Sun JC, Feng SQ. Efficacy and safety of bisphosphonates for low bone mineral density after kidney transplantation: A meta-analysis. Medicine (Baltimore). 2016;95(5):e2679. doi:10.1097/MD.0000000000002679.CrossRef Kan SL, Ning GZ, Chen LX, Zhou Y, Sun JC, Feng SQ. Efficacy and safety of bisphosphonates for low bone mineral density after kidney transplantation: A meta-analysis. Medicine (Baltimore). 2016;95(5):e2679. doi:10.​1097/​MD.​0000000000002679​.CrossRef
68.
go back to reference Wang J, Yao M, Xu JH, Shu B, Wang YJ, Cui XJ. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: A systematic review of randomized controlled trials. Osteoporos Int. 2016;27(5):1683–90. doi:10.1007/s00198-015-3465-7.CrossRefPubMed Wang J, Yao M, Xu JH, Shu B, Wang YJ, Cui XJ. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: A systematic review of randomized controlled trials. Osteoporos Int. 2016;27(5):1683–90. doi:10.​1007/​s00198-015-3465-7.CrossRefPubMed
70.
go back to reference Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14(10):2669–76.CrossRefPubMed Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14(10):2669–76.CrossRefPubMed
72.
go back to reference Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12(7):1530–7.PubMed Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12(7):1530–7.PubMed
74.
76.
go back to reference Yamamoto S, Suzuki A, Sasaki H, Sekiguchi-Ueda S, Asano S, Shibata M, et al. Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease. J Bone Miner Metab. 2013;31(1):116–22. doi:10.1007/s00774-012-0391-z.CrossRefPubMed Yamamoto S, Suzuki A, Sasaki H, Sekiguchi-Ueda S, Asano S, Shibata M, et al. Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease. J Bone Miner Metab. 2013;31(1):116–22. doi:10.​1007/​s00774-012-0391-z.CrossRefPubMed
78.
go back to reference Cayco AV, Wysolmerski J, Simpson C, Mitnick MA, Gundberg C, Kliger A, et al. Posttransplant bone disease: Evidence for a high bone resorption state. Transplantation. 2000;70(12):1722–8.CrossRefPubMed Cayco AV, Wysolmerski J, Simpson C, Mitnick MA, Gundberg C, Kliger A, et al. Posttransplant bone disease: Evidence for a high bone resorption state. Transplantation. 2000;70(12):1722–8.CrossRefPubMed
79.
80.
go back to reference De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: A randomized study. J Am Soc Nephrol. 2002;13(6):1608–14.CrossRefPubMed De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: A randomized study. J Am Soc Nephrol. 2002;13(6):1608–14.CrossRefPubMed
81.
go back to reference Cruzado JM, Moreno P, Torregrosa JV, Taco O, Mast R, Gomez-Vaquero C, et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2015; doi:10.1681/ASN.2015060622.PubMedCentral Cruzado JM, Moreno P, Torregrosa JV, Taco O, Mast R, Gomez-Vaquero C, et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2015; doi:10.​1681/​ASN.​2015060622.PubMedCentral
Metadata
Title
Osteoporosis in patients with diabetes after kidney transplantation
Authors
Elvira O. Gosmanova
Aidar R. Gosmanov
Publication date
01-03-2017
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 1/2017
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9397-5

Other articles of this Issue 1/2017

Reviews in Endocrine and Metabolic Disorders 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.